U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Dougherty's Pharmacy - 500635 - 05/14/2020
  1. Warning Letters

CLOSEOUT LETTER

Dougherty's Pharmacy MARCS-CMS 500635 —

Delivery Method:
VIA Electronic Mail
Reference #:
2017-DAL-WL-22
Product:
Drugs
Recipient:
Recipient Name
Stewart I. Edington
Recipient Title
President/CEO
Dougherty's Pharmacy

5924 Royal Lane
Suite 250
Dallas, TX 75230
United States

Issuing Office:
Office of Pharmaceutical Quality Operations Division II

United States

Mr. Edington:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter (WL # 2017-DAL-WL-22), dated May 12, 2017. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

If you have any question, please do not hesitate to contact me at John.Diehl@fda.hhs.gov.

Sincerely,
/S/
CDR John W. Diehl, M.S.
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

Back to Top